Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Investor Presentation (May 2024)

39 slides from Marinus Pharmaceuticals's investor presentation, May 8, 2024

  1. Slide 1: Corporate Presentation May 2024

    Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation May 2024

  2. Slide 2: Forward-looking statements

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe ha

  3. Slide 3: Ganaxolone Development Pipeline

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Development Pipeline 3 Ganaxolone is a positive allosteric GABAA receptor modulator with a well-defined MOA designed to treat patients suffering from seizure disorders. Ganaxolone is designed to modulate both synaptic and extrasynaptic

  4. Slide 4: Significant Near-term Milestones, Build on Commercial Success

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Program Indication 1H 2024 2H 2024 1H 2025 2H 2025 CDKL5 deficiency disorder Achieved profitability* Tuberous sclerosis complex Complete Phase 3 TrustTSC enrollment Phase 3 TrustTSC readout Potential filing for FDA Approval Potential Launch Develo

  5. Slide 5: Commercial Overview

    Commercial Overview Not for promotional use

  6. Slide 6: ZTALMY Has the Potential to Significantly Advance Epilepsy Treatment

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I ZTALMY® Has the Potential to Significantly Advance Epilepsy Treatment 6 Differentiated MOA addresses unmet need Well-characterized safety profile FDA-approved in CDD Scalable commercial infrastructure supports rapid expansion and adoption Signific

  7. Slide 7: ZTALMY Performance Metrics and Growth Drivers

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I ZTALMY® Performance Metrics and Growth Drivers 7 U.S. net product revenue of $7.5M for the first quarter of 2024 >125% growth from Q1 2023 Continued strong new patient enrollments Continued growth of new prescribers driving demand Achieved profita

  8. Slide 8: Tuberous Sclerosis Complex

    Tuberous Sclerosis Complex “Many individuals with TSC continue to experience uncontrolled seizures despite a cocktail of multiple antiepileptic drugs. Because new options are always needed, the TSC community welcomes clinical evaluation of new epilepsy treatments.” - Kari Luther Rosbeck, President &

  9. Slide 9: Tuberous Sclerosis Complex (TSC)

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Tuberous Sclerosis Complex (TSC) 9 CAUSE • Defect or mutation of TSC1 and/or TSC2 genes INCIDENCE • ~1 in 6,000 live births1 COMMON SYMPTOMS • Seizures, cognitive impairment, behavioral difficulties, skin/kidney/lung abnormalities, etc. EPILEPSY I

  10. Slide 10: TSC Phase 2 Trial Results

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I TSC Phase 2 Trial Results 10 * -200 -100 -80 -60 -40 -20 0 20 40 60 80 100 Percent reduction in TSC-associated seizure frequency =median 16.6% Secondary and Exploratory Analyses Primary Endpoint Results: 16.6% median reduction in TSC-associated se

  11. Slide 11: Phase 3 Protocol Refinements Informed by Phase 2 Tolerability

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Protocol Refinements Informed by Phase 2 Tolerability 11 Phase 3 Slower titration initially, designed to optimize tolerability and improve efficacy No (n=6) Yes (n=17) 0 5 10 15 20 25 30 Somnolence-related AE Percentreduction in TSC-associ

  12. Slide 12: Phase 3 Trial Overview

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Trial Overview 12 ► Enrollment: ~128 patients, targeting sites in the U.S., Western Europe, Canada, Israel, Australia and China • 90% powered to detect a 25% treatment difference • Statistical significance could be achieved with a treatmen

  13. Slide 13: TrustTSC Baseline Demographics

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I TrustTSC Baseline Demographics* 13 Age (mean [min-max]) 15 [1-50] Gender 52% male 48% female Failed Therapies* (mean) 4.8 Baseline Seizure Rate (median, per 28 days) 50 DB Discontinuation Rate** ~7% 2 discontinuations (<2%) due to somnolence-relat

  14. Slide 14: Anticipated Commercial Expansion into Tuberous Sclerosis Complex

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 14 Influential Advocacy Community Reflects the values and priorities of the TSC community and addresses the unique challenges associated with rare genetic epilepsy Significant Market Opportunity TSC can be readily diagnosed, and a substantial port

  15. Slide 15: Addressable Patient Population

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Addressable Patient Population ~2,000 12,700 44%4,5 CDD Patients6 Refractory* CDD Patients Diagnosed TSC Prevalence Epileptic TSC CDD 29,000 84%3 34,000 75%2 48,000 1/6000 incidence1 Unlocking a 4-5x Growth Opportunity for ZTALMY® in TSC 15 1TSC A

  16. Slide 16: Plans to Leverage Existing ZTALMY Infrastructure in TSC

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Plans to Leverage Existing ZTALMY® Infrastructure Expected to Yield Significant Returns in TSC 16 16 COMMERCIAL INFRASTRUCTURE Addition of 12-16 RAMs to reach key targets, including 17 TSC COEs MARKET POSITIONING Distinct TSC positioning: First Ph

  17. Slide 17: Significant Growth Potential with Expansion into Larger Indications

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Significant Growth Potential with Expansion into Larger Indications 17 ~12k refractory patients in the U.S. ~48k patients in the U.S. ~2k patients in the U.S. CDKL5 Deficiency Disorder Approved in the U.S. and EU Tuberous Sclerosis Complex Potenti

  18. Slide 18: Second Generation Product Development

    Second Generation Product Development

  19. Slide 19: Second Generation Ganaxolone Goals

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Ganaxolone 19 Goals Target Oral Pharmacokinetic Profile Increase efficacy Consistent delivery to achieve target plasma concentration Improve tolerability Optimize PK profile to reduce Cmax-related adverse effects Reduce dosing fr

  20. Slide 20: Next Steps: Prodrug and Ganaxolone Reformulation

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Next Steps: Prodrug and Ganaxolone Reformulation 20 Ganaxolone Prodrug Oral prodrug candidate selected Goals: • Optimize PK parameters for efficacy, tolerability and dosing frequency • Increase absorption (oral), solubility (IV) Preclinical IND-en

  21. Slide 21: Status Epilepticus

    Status Epilepticus

  22. Slide 22: Status Epilepticus Overview

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus Overview 22 Status Epilepticus = Condition resulting from either the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms which lead to: • abnormally prolonged seizures (after time p

  23. Slide 23: Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment 23 Experimental PK – plasma and brain1 Brain and plasma concentration after ganaxolone 3 mg/kg IM in mice Human PD – EEG changes2 EEG bispectral index in healthy volunteers follo

  24. Slide 24: Refractory Status Epilepticus Trial (RSE) Design

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Treatment Period Loading Dose Maintenance Taper Phase 2 Refractory Status Epilepticus Trial (RSE) Design 24 • Diagnosis of convulsive or non-convulsive SE • Failed at least one 2nd line IV AED but had not progressed to 3rd line IV anesthetics Bolu

  25. Slide 25: Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect 25 Data presented at AES 2019 AEDs – antiepileptic drugs Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status-free through

  26. Slide 26: RAISE: Phase 3 Trial in Refractory Status Epilepticus

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE: Phase 3 Trial in Refractory Status Epilepticus 26 STUDY POPULATION INTERVENTION CO-PRIMARY ENDPOINTS KEY SECONDARY ENDPOINTS Onset of Action: Proportion of patients with SE cessation within 30 minutes Durability of Effect: Proportion of pat

  27. Slide 27: Approach to SRSE

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I ► SRSE-specific dosing approach • ↓Cmax but ↑ AUC • 3-month oral wean • Ganaxolone 833mg/day x48h ➛ 1,050mg/day x 168h • Captisol® 50gm/day ➛ 63gm/day Approach to SRSE 27 29 patients with SRSE treated with IV ganaxolone to date 14 with regimen sim

  28. Slide 28: Super Refractory Status Epilepticus: Ganaxolone Experience to Date

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Super Refractory Status Epilepticus: Ganaxolone Experience to Date 28 New onset refractory status epilepticus (NORSE) Febrile illness-related epilepsy syndrome (FIRES) Lennox-Gastaut syndrome PCDH-19 related epilepsy Autoimmune encephalitis Herpes

  29. Slide 29: Financial Update

    Financial Update

  30. Slide 30: Financial Overview

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Financial Overview 30 Analyst Coverage*: Cantor Fitzgerald: Charles C. Duncan, Ph.D. T.D. Cowen: Joseph Thome, Ph.D. H.C. Wainwright & Co: Douglas Tsao Jefferies: Andrew Tsai JMP Securities: Jason N. Butler, Ph.D. Ladenburg Thalmann: Michael Higgi

  31. Slide 31: Driving Global Access of ZTALMY (ganaxolone)

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Driving Global Access of ZTALMY® (ganaxolone) 31 Europe: Collaboration agreement with Orion Corporation for ganaxolone in CDD, TSC, RSE • Up to €90 million of development, commercial, and sales milestones1 ; tiered royalties in the low double-digi

  32. Slide 32: Intellectual Property

    Intellectual Property

  33. Slide 33: Multiple Layers Of Potential Protection

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Multiple Layers Of Potential Protection 33 Orphan drug designations for CDD and PCDH19 provide 7 and 10 years regulatory exclusivity in U.S. and EU, respectively. Orphan drug designation for SE provides 7 years regulatory exclusivity in U.S. U.S.

  34. Slide 34: Appendix

    Appendix (® MARINUS

  35. Slide 35: A Comprehensive Commercial Strategy to Grow the ZTALMY Brand

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I A Comprehensive Commercial Strategy to Grow the ZTALMY® Brand 35 Patient identification Activate the caregiver community Focused education to HCPs to establish ZTALMY as the standard of care for CDD seizure management Continuously enhance the pati

  36. Slide 36: Phase 3 CDD Marigold Trial Data and Safety Summary

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 36 Ganaxolone Placebo 0 10 20 30 40 Median Percent Reduction 28-day Frequency of Major Motor Seizures 30.7% 6.9% *Wilcoxon Rank-Sum Test **Hodges-Lehman Estimate of Median Dif erence Patients taking ganaxolone experienced a significant reduction i

  37. Slide 37: Average Ganaxolone Levels Correlate with Seizure Reduction

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Average Ganaxolone Levels Correlate with Seizure Reduction 37 • Logarithms of plasma ganaxolone level and percentage change in major motor seizure frequency were negatively correlated • Patients in the Medium and High ganaxolone level groups had a

  38. Slide 38: Phase 3 Open Label Extension Data in CDD

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Patients who remained in the clinical trial at 2 years experienced sustained reduction in MMSF1 ► Following the pivotal trial, 88 out of 101 patients entered an open-label extension study to evaluate the ongoing safety and efficacy of ZTALMY.1 ► T

  39. Slide 39: Phase 1 Single Ascending Dose (SAD) Study

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 1 Single Ascending Dose (SAD) Study 39 39 Mean Cmax (ng/mL) Mean AUC0-t (h*ng/mL) 41% 31% 38% 18% 18% 14% Study design Ganaxolone reformulation demonstrated linear kinetics at single doses from 100-1200 mg • Single dose PK study in healthy a

Marinus Pharmaceuticals — Investor Presentation (May 2024) on 6ix